LICENSE AGREEMENTS (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2012	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2012	Mar. 31, 2022	Jun. 22, 2014
BRIUMVI (Ublituximab)
License Agreements
Upfront fee	$ 2,000,000.0			$ 2,000,000
Income taxes	$ 300,000
Term after first commercial sale	15 years	15 years
Deferred Revenue		$ 400,000	$ 500,000
License revenue		38,000			$ 38,000
Deferred Revenue, Current		200,000	200,000
Expenses incurred		25,000,000.0
Additional payments on achievement of certain milestones		18,000,000.0
Accrued Royalties		800,000
BRIUMVI (Ublituximab) | Maximum [Member]
License Agreements
Potential milestones payable		5,000,000.0
UKONIQ (umbralisib) [Member]
License Agreements
Expenses incurred		24,000,000.0
Potential milestones payable						$ 175,000,000
Accrued Royalties		$ 0
Royalty Expense			200,000
Royalty payable			$ 3,000